Trazodone has been reported to inhibit the PERK–eIF2α signaling pathway, which is overactivated in Alzheimer’s disease and contributes to abnormal amyloid precursor protein (APP) translation and Aβ accumulation (Halliday et al., 2015); (Rohe et al., 2009). Here, APP is linked to early-onset autosomal dominant Alzheimer disease.